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Expressed in branchial arches and osteoblast-lineage cells, special AT-rich sequence-binding protein (SATB2) is
responsible for preventing craniofacial abnormalities and defects in osteoblast function. In this study, we
transduced SATB2 into murine adult stem cells, and found that SATB2 significantly increased expression levels
of bone matrix proteins, osteogenic transcription factors, and a potent angiogenic factor, vascular endothelial
growth factor. Using an osterix (Osx) promoter-luciferase construct and calvarial cells isolated from runt-related
transcription factor 2 (Runx2)-deficient mice, we found that SATB2 upregulates Osx expression independent of
Runx2, but synergistically enhances the regulatory effect of Runx2 on Osx promoter. We then transplanted
SATB2-overexpressing adult stem cells genetically double-labeled with bone sialoprotein (BSP) promoter-driven
luciferase and b-actin promoter-driven enhanced green fluorescent protein into mandibular bone defects. We
identified increased luciferase-positive cells in SATB2-overexpressing groups, indicating more transplanted cells
undergoing osteogenic differentiation. New bone formation was consequently accelerated in SATB2 groups. In
conclusion, SATB2 acts as a potent transcription factor to enhance osteoblastogenesis and promote bone re-
generation. The application of SATB2 in bone tissue engineering gives rise to a higher bone forming capacity as a
result of multiple-level amplification of regulatory activity.
Introduction
As a nuclear matrix protein, special AT-rich sequence-binding protein 2 (SATB2) activates gene transcription
through binding to nuclear matrix-attachment regions,
which are AT-rich DNA sequences implicated in the regu-
lation of gene transcription by altering the organization of
eukaryotic chromosomes, structurally defining the borders of
chromatin domains, and augmenting the potential of en-
hancers to act over large distances.1–3 While binding to AT-
rich DNA elements, SATB2 modifies the chromatin structure
through interacting with histone deacetylase 1 and metas-
tasis-associated protein 2, and thus plays an important role
in integrating genetic and epigenetic signals.4 The matrix-
attachment region-binding ability and transcriptional acti-
vation potential of SATB2 can be increased by mutations of
two lysines that remove the inhibitory modification by the
covalent conjugation of the small ubiquitin-related modifier.2
The SATB2 gene lies in a gene-poor region of 2q32–q33, on
which a locus for isolated cleft palate is located.5 In 2003
SATB2 was identified as the cleft palate gene on 2q32-q33,
and haploinsufficiency of SATB2 was reported to affect
multiple systems in humans.6 Indeed, an individual with a
de novo germline nonsense in SATB2 was reported to exhibit
generalized osteoporosis, profound mental retardation, and
craniofacial dysmorphism, including cleft palate, mandibular
hypoplasia, and protruding incisors.7 In another four pa-
tients with an interstitial deletion of chromosome 2q32–q33,
similar clinical findings were reported including growth re-
tardation, distinct facial dysmorphism, and a cleft or high
palate which was considered to be the result of hemizygosity
for SATB2.8 Based on the common clinical features in indi-
viduals with small deletions of 2q32-q33, researchers sug-
gested that microdeletions of 2q32-q33 constitute a distinct
syndrome characterized with palate abnormalities, tooth
anomalies, growth retardation, and behavior problems
(OMIM 612313), and SATB2 haploinsufficiency is the etio-
logical factor for, at least, some of the clinical features asso-
ciated with this syndrome.8,9
SATB2 and murine Satb2 are highly conserved (99.6%),
and animal studies have recently confirmed an essential role
of SATB2 in proper facial patterning of the embryo and in
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normal bone development.9 Satb2-/- embryos showed
multiple craniofacial defects, including a significant trunca-
tion of the mandible and a cleft palate,10,11 which resemble
the clinical manifestations observed in humans with genetic
aberrations in the SATB2 gene.11 Satb2 -/ - mice also ex-
hibited defects in osteoblast differentiation and function,
which consequently delayed bone formation and minerali-
zation.10 The defects observed in Satb2-null mice have been
attributed to an increased expression of specific members of
the Hox gene clusters and a decreased expression of osteo-
blast-specific genes, whereby SATB2 was shown to regulate
these genes at the chromatin level.10
Vertebrate skeletogenesis involves two processes, skeletal
patterning and osteoblast differentiation. Previous studies
clearly demonstrated that SATB2 plays pivotal roles in both
processes, suggesting that SATB2 can be used as an ideal
bioactive factor to overcome the hurdles in craniofacial and
dental regeneration by providing functional bone tissue with
natural morphology and physiological properties. In this
study, we further investigated the role of SATB2 in osteo-
genic differentiation, and made the first step to the applica-




The mouse Satb2 cDNA was released from pBs-SK-Satb2
(from Dr. Rudolf Grosschedl, Max-Planck Institute of Im-
munobiology, Freiburg, Germany),10 and was ligated into
pBABE-hygro (Addgene ID: 1765) and pcDNA3.1( + ) (In-
vitrogen). A 4.1-kb DNA fragment was released from pBs-
SK-Satb2 by double digestion with NotI/EcoRV, blunted, and
self-ligated, resulting in a plasmid with a 1000 bp fragment of
Satb2 cDNA. The 1000 bp fragment of Satb2 cDNA was then
released and ligated into the plasmid pBluescript-SKII (+ ),
creating pBs-SKII-Satb2 (1000 bp) to be used to prepare a
1000 bp Satb2 probe for in situ hybridization. pcDNA3.1-
Bmp4 was created by subcloning mouse Bmp4 polymerase
chain reaction (PCR) fragments into pcDNA3.1( + ) (Invitro-
gen). The full-length osterix (Osx) promoter-luciferase
construct (- 2020/+ 13) was produced in Dr. Hicham Drissi’s
laboratory at University of Connecticut Health Center,
Farmington, CT.12 A plasmid encoding Runx2 (pCMV-Osf2/
Cbfa1) was a gift from Dr. Karsenty’s laboratory (College
of Physicians and Surgeons, Columbia University, New
York, NY).
In situ hybridization
In situ hybridization for the detection of in vivo distribution
of the Satb2 mRNA was performed essentially as described
previously.13 Briefly, E14.5 embryos were isolated from
C57BL/6J mice, fixed in 4% paraformaldehyde, and em-
bedded in paraffin. Tissue sections, 6mm in thickness, were
mounted on glass slides for in situ hybridization studies. The
1000 bp Satb2 cDNA fragment was released from pBs-SKII-
Satb2 (1000 bp) and in vitro transcribed using a MAXIscript
In Vitro Transcription Kit (Ambion) and 5¢-[35S]UTP (1250Ci/
mmol). The tissue sections were then deparaffinized and
incubated with 35S-labeled RNA probe. Control sections
were incubated with sense cRNA probes under the same
conditions. The tissue sections were then dipped in Kodak
NTB-2 emulsion (Eastman Kodak Company), and developed
after 3 days of exposure. Tissue sections were counterstained
with hematoxylin and eosin (H&E), and observed using a
Nikon Eclipse E600 microscope.
Cell culture
MC3T3-E1 murine osteoblast-like cells were maintained in
alpha minimum essential medium (a-MEM) with 10% fetal
bovine serum and antibiotics. Murine osteoblast precursor
cells in the form of calvarial cells were isolated and routinely
cultured as described previously.14 Dental follicle cells
(DFCs) and bone marrow stromal cells (BMSCs) were ob-
tained from 5–7-day-old or 7-week-old BSP-Luc/ACTB-
EGFP mice, respectively, and were cultured as described
previously.15,16 Briefly, for DFCs, bilateral first mandibular
molar germs were dissected and digested with 1% trypsin at
4C for 1.5 h. The dental follicle tissues were then isolated
and cultured in a-MEM supplemented with 20% fetal bovine
serum and antibiotics. Bone siloprotein-Luc/ACTB-EGFP
mice were genetically double labeled with a luciferase re-
porter gene driven by a bone sialoprotein (BSP) promoter and
an enhanced green fluorescent protein (EGFP) driven by a beta-
actin promoter.15
Preparation of retroviral vectors and cell infection
pBABE-hygro-Satb2 and packaging vector pCL-Eco were
co-transfected into HEK-293T cells using Lipofectamine Re-
agent (Invitrogen). Forty-eight hours after transfection, the
supernatant filtered through a 0.45 mm filter (Millipore) was
used to infect the cells with polybrene at a final concentration
of 8mg/mL. The empty retroviral vector pBABE-hygro was
also packaged and used as a control. Stably infected cells
were selected using hygromycin B (Invitrogen).
Transient cell transfection and luciferase assay
For transient transfection, the full-length Osx promoter-
luciferase construct (- 2020/+ 13) and a b-gal control plasmid
were co-transfected with pcDNA3.1-Satb2, or pCMV-Osf2/
Cbfa1, or both into HEK-293 and MC3T3-E1 cells using li-
pofectamine Reagent (Invitrogen). Forty-eight hours after
transfection, luciferase and b-gal levels were determined
using a luminometer (Lumat LB 9501; EG&G Berthold) and
b-gal detection kit II (BD Clontech), respectively. Luciferase
activity was normalized to b-galactosidase activity.
Real-time reverse transcription–PCR
for mRNA analysis
Quantitative real-time reverse transcription–PCR assay for
mRNA analysis was performed using iQ SYBR Green Su-
permix (Bio-Rad Laboratories) on a Bio-Rad iQ5 thermal
cycler (Bio-Rad Laboratories). The evaluation of relative
differences in PCR product amounts was carried out by the
comparative cycle threshold method, using glyceraldehyde
3-phosphate dehydrogenase as a control.
RNA interference and Western blot
Calvarial osteoblasts were transfected with SATB2 siRNAs
or scrambled control siRNAs (Santa Cruz Biotechnology)
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following the recommendations of the manufacturer. Whole
protein lysates were prepared essentially as described pre-
viously.17 Antibodies for SATB2 (Abcam) and b-actin (Santa
Cruz Biotechnology) were used in the Western blot analysis.
The secondary antibodies were horseradish peroxidase-
linked goat-anti rabbit IgG (Santa Cruz). Blots were observed
using electrogenerated chemiluminescence (ECL) reagents
from Pierce Biotechnology.
Animal surgery
Collagen matrices purchased from Collagen Matrix, Inc.,
were trimmed into appropriate size (2.5 · 2· 1mm), and
static seeding techniques were used to transfer SATB2-
overexpressing DFCs or BMSCs into the matrix. Briefly, cell
suspension at the concentration of 106 cells/mL was applied
to the respective sponges, which were incubated for 1 h at
37C and then transplanted to the bone defect sites. Man-
dibular bone defects were created in 5-month-old B6D2F1
male mice ( Jackson Laboratory), the strain from which our
mBSP9.0Luc transgenic mice were derived.13 Bone defects,
1.5mm in diameter, were created on the bone overlying the
mandibular first molar. The generated bone defects were
then transplanted with collagen matrix seeded with SATB2-
overexpressing BMSCs or DFCs, or corresponding control
cells. Animals were sacrificed 7 days after surgery.
Mice were maintained and used in accordance with rec-
ommendations in The Guide for the Care and Use of Laboratory
Animals prepared by the Institute on Laboratory Animal
Resources, National Research Council (DHHS Publ. NIH 86–
23, 1985), and by guidelines established by the Institutional
Animal Care and Use Committee of the Tufts-New England
Medical Center (Boston, MA).
Histomorphometric analysis
The isolated bone samples were fixed in 10% neutral-
buffered formalin solution, decalcified using 0.2N HCL, and
embedded in paraffin. Tissue sections, 6 mm in thickness,
were mounted on glass slides and H&E staining was per-
formed. Digital images were taken with a Nikon Eclipse E600
microscope and analyzed by Spot Advanced software (Di-
agnostic Instruments). Newly formed bone areas, expressed
as a percentage (area of newly formed bone/area of original
wound · 100), were measured essentially as described pre-
viously.18
Immunohistochemical staining
Immunohistochemical staining (IHC) was performed us-
ing a Histostaining Kit from Zymed Laboratories, Inc. The
IHC procedures were described in our previous publica-
tions.13 Control sections were incubated with an irrelevant
antibody (anti-human CD4 lymphocyte antigen) to estimate
back-ground staining. Primary antibodies against SATB2
(Abcam), firefly luciferase (Santa Cruz Biotechnology), GFP
(Clontech), and BSP (a gift from Dr. Larry Fisher, NIH/
NIDCR) were purchased. For SATB2 IHC staining, the
Histostain-SP Kit (DAB, Broad Spectrum; Invitrogen) was
used. For IHC staining of luciferase, GFP, and BSP, the
Histostain-SP Kit (AEC, Broad Spectrum; Invitrogen) was
used. Stained slides were observed under a Nikon Eclipse
E600 microscope and cell counts were performed within the
newly formed bone area. The numbers of BSP, GFP, and
luciferase-positive cells were normalized to the total number
of cells in the wound sites.15
Statistical analysis
All results were expressed as means – standard error of the
mean of three or more independent experiments. One-way
analysis of variance was used to test significance using the
software package Origin 6.1 (OriginLab). Values of p < 0.05
were considered statistically significant.
Results
Expression pattern of SATB2 in mouse embryos
and adult bone tissues
To get first-hand information of SATB2 expression pattern
in the jaws and teeth, we performed in situ hybridization of
the head from wild-type mice (C57BL/6J) at E14.5. We found
that Satb2 mRNA was highly expressed in the dental mes-
enchymal components of incisor tooth germ (Fig. 1A, B).
Moreover, the signal of Satb2 mRNA was intense in the de-
veloping palate and mandibular bone matrix, but was weak
in Meckel’s cartilage. The strongest expression of Satb2
mRNA was observed in the edges of the developing palatine
processes, which were growing toward each other (Fig. 1C–
F). The expression pattern of Satb2 mRNA in jaws and teeth
indicated that SATB2 plays an important role in the devel-
opment of these organs. We also performed IHC staining to
monitor the expression of SATB2 in E14.5 mouse embryos at
the protein level. We observed intense SATB2 signals in the
nucleui of osteoblasts aligning on the surface of the devel-
oping mandibular bone in the E14.5 mouse embryos (Fig.
2A–D). We also found abundant SATB2-positive cells in the
mesenchymal component of the incisor tooth germs (Fig. 2E)
and the developing palate (Fig. 2F, G) at this developmental
stage. Interestingly, we also found a few SATB2-positive
chondrocytes in the Meckel’s cartilage, which were seemed
to be at their hypertrophic stage (Fig. 2B, D).
SATB2 has been reported to be expressed in the breast
tissues and leukocytes in adult human beings.7,19 In animal
models, SATB2 was found to be expressed in adult central
nervous system.20,21 However, currently it is still unclear
whether SATB2 is also expressed in adult bone tissues. In
this study, we performed IHC staining on femoral bone tis-
sue sections derived from 2-month-old wild-type mice. On
these tissue sections, we detected strong signals of SATB2 in
the osteoprogenitor cells aligning on the inner surface of the
adult femurs (Fig. 2H, I) and the surface of the trabecular
bone at the growth plate area (Fig. 2J, K). We also created
1.5mm bone defects on the mandibles of 5-month-old
B6D2F1 mice and monitored the expression of SATB2 pro-
tein in the mandibular bone defects. As shown in Figure 2L
and M, the collected mandibular bones were cut in the hor-
izontal direction, and we observed intense SATB2 staining in
most of the osteoblasts existing in the newly formed bone
area of the mandibular bone defects.
SATB2 enhances expressions of bone matrix proteins
and osteogenic transcription factors in BMSCs
and DFCs
BMSCs and DFCs were known to be able to differentiate
into hard tissue forming cells (osteoblasts or cementoblasts),
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and bone marrow mononuclear cells were recently found to
promote tissue regeneration in critical size rat cranial defects
without the need for in vitro culture, expansion, and purifi-
cation.22 To investigate the effect of SATB2 on the differen-
tiation processes of BMSCs and DFCs, we transiently
transfected pcDNA3.1-Satb2 into BMSCs and DFCs, and
determined gene expression changes. Considering the potent
osteogenic inductivity of bone morphogenetic proteins
(BMPs), pcDNA3.1-Bmp4 was also transfected into BMSCs to
serve as a positive control. Cells transfected with the empty
vector (pcDNA3.1) served as negative controls. We found
that 72 h after transfection, SATB2-overexpressing BMSCs
showed increased mRNA levels of BSP, runt-related tran-
scription factor 2 (Runx2), Osx, and vascular endothelial
growth factor A (VEGFA) compared with the control cells.
BMP4 induced the expression of SATB2 at the mRNA level,
FIG. 2. Immunohistochemical
staining of the heads from C57bl/6j
mice at E14.5 (A–G), the femurs
from 2-month-old C57bl/6j mice
(H–K), and the mandubular bone
defects created in the 5-month-old
B6D2F1 mice (L, M). (A, B) Intense
SATB2 signals are detected in the
nucleui of osteoblasts aligning on
the surface of the developing man-
dibular bone in the E14.5 mouse
embryos. Some of the chondrocytes
in the Meckel’s cartilage are also
positively stained. (B) Higher mag-
nification of the squared area in A.
(C–E) In addition to the strong
staining in the mandibular osteo-
blasts, abundant SATB2-positive
cells are observed in the mesenchy-
mal component of the lower incisor
tooth germs. (D) Higher magnifica-
tion of the squared area in C. (E)
Higher magnification of the circled
area in C. (F, G) The developing
palate is filled with SATB2-positive
cells. (G) Higher magnification of
the squared area in F. (H, I) Strong
signals of SATB2 are observed in the
nuclei of osteoprogenitor cells
aligning on the inner surface of the
adult femurs. (I) Higher magnification of the squared area in H. ( J, K) At the growth plate area of the adult femurs, many
SATB2-positive cells attach to the surface of the trabecular bone. (K) Higher magnification of the squared area in J. (L, M)
Most of the osteoblasts existing in the newly formed bone area of the mandibular bone defects are strongly stained. The
mandibular bones were cut in the horizontal direction. (M) Higher magnification of the squared area in L. T, tongue; LM,
lower molar; MB, mandibular bone; MC, Meckel’s cartilage; LI, lower incisor; P, palate; F, femur; BM, bone marrow; GP,
growth plate; NB, newly formed bone; M1, roots of the first mandibular molar; M2, roots of the second mandibular molar;
arrow, positively stained cells; arrow head, negatively stained cells. Color images available online at www.liebertonline.com/tea
FIG. 1. In situ hybridiza-
tion (A, C, E) and H&E
staining (B, D, F) of the
heads from wild-type mice
(C57bl/6j) at E14.5. (A, B)
The SATB2 gene is strongly
expressed in mesenchymal
components of incisors. (C,
D) SATB2 expression is high
in bone matrix of mandible,
but is weak in the Meckel’s
cartilage. (E, F) SATB2 ex-
pression in the edges of de-
veloping palatine processes
is prominent. m, meckel’s
cartilage; dm, dental mesenchyme; eo, enamel organ; bm, bone matrix; um, upper molar. H&E, hematoxylin and eosin;
SATB2, special AT-rich sequence-binding protein. Color images available online at www.liebertonline.com/tea
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but the mRNA levels of BSP, Runx2, Osx, and VEGFA in-
duced by BMP4 showed a different pattern compared with
those induced by SATB2 (Fig. 3A). We also found that
SATB2 overexpression in DFCs significantly enhanced the
mRNA levels of BSP and Runx2 (Fig. 3B). Using real-time
reverse transcription–PCR analysis, Satb2 mRNA could be
detected in primary DFCs isolated from molars at the root
forming stage (data not shown), although it was demon-
strated that SATB2 was not expressed in early develop-
mental stages of molar tooth germs.10 As shown in Figure 3B,
Satb2mRNA was also detected in DFCs isolated from molars
at the root forming stage that were transfected with the
empty vector (pcDNA3.1). We then specifically knocked
down SATB2 protein level in calvarial osteoblasts using
siRNAs specifically targeting SATB2. We found that a lower
protein level of SATB2 resulted in decreased mRNA levels of
Runx2, Osx, BSP, and osteocalcin (Fig. 3C, D).
SATB2 and Runx2 synergistically upregulate
Osx expression
To test whether SATB2 upregulates Osx expression level
in a Runx2-dependent way, calvarial cells were harvested
from Runx2 +/ - and Runx2 -/ - mouse fetuses and cultured
in a non-osteoinducive medium. Overexpression of SATB2
was achieved through infection with pBABE-hygro-Satb2.
Cells infected with pBABE-hygro served as control. As
shown in Figure 4A and B, SATB2 overexpression resulted in
elevated Osx mRNA levels in both Runx2 +/ - and Runx2 -/ -
calvarial cells compared with their corresponding control
cells. We then co-transfected the full-length Osx promoter-
luciferase construct (- 2020/+ 13) with pcDNA3.1-Satb2, or
pCMV-Osf2/Cbfa1, or both into HEK-293 and MC3T3-E1
cells. As a result of elevated SATB2 level, the activity of the
Osx promoter was enhanced by approximately 1.8- and 1.6-
fold, respectively, in MC3T3-E1 and HEK-293 cells. Runx2
overexpression upregulated the activity of the Osx promoter
by 2.52 and 1.8-fold, respectively, in MC3T3-E1 and HEK-293
cell lines. The most prominent increase in Osx promoter ac-
tivity was observed in cells co-transfected with both
pcDNA3.1-Satb2 and pCMV-Osf2/Cbfa1, suggesting that
SATB2 and Runx2 act synergistically in regulating the ex-
pression level of Osx (Fig. 4C).
SATB2 overexpression in adult stem cells
promotes osteogenic differentiation
and bone tissue regeneration
DFCs and BMSCs used in this study were obtained from
BSP-Luc/ACTB-EGFP mice.15 SATB2 overexpression in
BMSCs and DFCs were achieved through infection with
pBABE-hygro-Satb2. Cells infected with pBABE-hygro
served as controls. Infected cells were transplanted into the
mandibular wound sites created in 5-month-old B6D2F1
mice, the strain from which our mBSP9.0Luc transgenic mice
were derived. The surgical procedures were illustrated in
Figure 5A and B, and in Figure 5C we showed an isolated
mandibular bone with the 1.5mm bone defect. As shown in
Figure 5D, the mandibular bone samples were dissected,
embedded in paraffin, and microtoned in the coronal direc-
tion. The 6-mm-thick tissue sections were numbered, and the
tissue sections positioned in lines a, b, and c from each ani-
mal were collected for further quantitative analysis (Fig. 5D,
E). As shown in Figure 6, the newly formed bone area was
evaluated on tissue sections using a double-blinded method
to prevent observer’s bias. For better comparison, we only
FIG. 3. SATB2 upregulated expression
levels of bone matrix proteins and osteo-
genic transcription factors. (A)BMSCswere
transiently transfected with pcDNA3.1-
Satb2 or pcDNA3.1-Bmp4. BMSCs tran-
siently transfected with pcDNA3.1 served
as the negative control. SATB2 over-
expression in BMSCs enhanced the mRNA
levels of BSP, Runx2, Osx, and vascular
endothelial growth factor A. BMP4 in-
creased the mRNA level of SATB2. Data
were represented as mean–SEM. *p<0.05,
versus control group (pcDNA3.1 group);
**p<0.05, SATB2 group versus BMP4
group. (B) DFCs were transiently trans-
fected with pcDNA3.1-Satb2. DFCs tran-
siently transfected with pcDNA3.1 served
as the negative control. SATB2 over-
expression in DFCs also enhanced the
mRNA levels of BSP and Runx2. Data were
represented as mean–SEM. *p<0.05,
SATB2 group versus control group
(pcDNA3.1 group). (C) Calvarial osteo-
blasts were transfected with SATB2 siRNAs or scrambled control siRNAs (Santa Cruz Biotechnology). SATB2 protein level in these
calvarial osteoblasts was dramatically knocked down by the siRNAs specifically targeting SATB2. (D) Calvarial osteoblasts
transfected with SATB2 siRNAs or scrambled control siRNAs were also subjected to real-time reverse transcription–polymerase
chain reaction analysis. Cells transfected with SATB2 siRNAs displayed decreased mRNA levels of Runx2, Osx, BSP, and OC
compared with the cells transfected with scrambled control siRNAs. Data were represented as mean–SEM. *p<0.05, versus
scrambled control group. BMSC, bonemarrow stromal cell; SEM, standard error of themean; DFC, dental follicle cells; BMP 4, bone
morphogenetic protein 4; Osx, osterix; Runx2, runt-related transcription factor 2; BSP, bone sialoprotein; OC, osteocalcin.
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illustrated tissue sections collected from position c in the
Figure 6. The area within the original bone lesion was assessed
by digitizing the reversal line in the bone at the cut margin of
the original wound outline. We then digitized the newly
formed bone area in the bone compartment of the wound. All
of the histomorphometric analysis was performed using Spot
Advanced software (Diagnostic Instruments), and the newly
formed bone area was expressed as a percentage (area of
newly formed bone/area of original wound· 100).
Observation on H&E-stained sections revealed increased
newly formed bone tissues in bone defects treated with
SATB2-transduced BMSCs (SATB2-BMSC group, Fig. 6B)
and DFCs (SATB2-DFC group, Fig. 6E), compared with the
corresponding control groups, control-BMSC group (Fig. 6A),
and control-DFC group (Fig. 6D), respectively. Histomorpho-
metric analysis confirmed increased newly formed bone area
in the two SATB2 groups, indicating that bone tissue regen-
eration was accelerated by SATB2 overexpression (Fig. 6C, F).
IHC staining was then performed in SATB2-BMSC group
and control-BMSC group to track and evaluate the osteo-
genic ability of the transplanted adult stem cells. As men-
tioned above, the adult stem cells used in our in vivo
experiment were isolated from a double-labeled transgenic
mouse line, BSP-Luc/ACTB-EGFP mice.15 Briefly,
mBSP9.0Luc mice contain a BSP promoter linked to the lu-
ciferase reporter gene (mBSP9.0Luc).13 A second marker,
GFP, was introduced into the mBSP9.0Luc mice by cross
breeding these mice with BACT-EGFP mice in which an
EGFP is driven by a beta-actin promoter and cytomegalovi-
rus enhancer (#3291, Jackson Lab). The resulted transgenic
mice were named as BSP-Luc/ACTB-EGFP mice. All adult
stem cells isolated from the BSP-Luc/ACTB-EGFP mice ex-
press GFP, and the expression of luciferase is switched on as
the cells differentiate into osteoblasts. Therefore, in our
study, after the adult stem cells isolated from the BSP-Luc/
ACTB-EGFP mice were transplanted into the recipient mice,
GFP staining can be used to track the fate and migration of
these adult stem cells, whereas Luciferse staining serves as a
marker for osteogenic differentiation of the transplanted
cells. Using IHC staining, the localization of BSP, luciferase,
or GFP was studied on tissue sections collected at the posi-
tions of lines a, b, and c as indicated in Figure 5D. At least
three tissue sections from each position and altogether at
least nine sections from each animal were used for cell
counting. Cell counts were performed within the newly
formed bone area, and a positively stained cell was defined
as a purple-stained nucleus surrounded by red staining. The
final data were represented by the ratio of the positively
stained cells versus total cells.
In both groups, positive EGFP and luciferase signals could
be detected, indicating transplanted exogenous BMSCs and
transplanted BMSCs undergoing osteogenic differentiation,
respectively (Fig. 7A). Positive cell counting showed a higher
number of luciferase-positive cells in SATB2-BMSC group
than in control-BMSC group, indicating that SATB2 over-
expression significantly enhanced the osteogenic differenti-
ation of transplanted BMSCs (Fig. 7B). Consistent with this
result, more BSP-positive cells were observed in SATB2-
BMSC group than in the control-BMSC group (Fig. 7C). No
statistically significant difference in the number of EFGP-
positive cells was detected between SATB2-BMSC group and
control-BMSC group (Fig. 7D).
FIG. 4. Effects of SATB2 and Runx2 on the expression level
of Osx. (A, B)Murine osteoblast precursor cells in the form of
calvarial cells were isolated from Runx2 +/ - and Runx2 -/-
mice and infected with pBABE-hygro-Satb2 (SATB2) or
pBABE-hygro (control). Expression levels of SATB2 (A) and
Osx (B)were monitored using real-time reverse transcription–
polymerase chain reaction analysis. Data were represented as
mean– SEM. *p< 0.05, SATB2 group versus control group. (C)
HEK-293 cells or MC3T3-E1 cells were co-transfected with
pOsx2.0kb-luc and a CMV b-gal construct. Empty vector
(control), or pcDNA3.1-Satb2 (SATB2), or pCMV-Osf2/Cbfa1
(Runx2), or both pcDNA3.1-Satb2 (SATB2) and pCMV-Osf2/
Cbfa1 (SATB2 +Runx2) were also co-transfected. Luciferase
assays were performed to evaluate the effect of SATB2 and
Runx2 on Osx promoter activity. Data were represented as
mean – SEM. *p < 0.05, versus control group.
1772 ZHANG ET AL.
Discussion
In our previous studies, we have applied osteogenic
molecules in bone tissue engineering to promote osteogenic
differentiation and bone regeneration.18,23 Using a mouse
periodontal window wound model, we found that as a result
of Runx2 overexpression, local stem cells were induced to
differentiate toward osteoblast-lineage cells and participated
in the regenerative processes more actively, which signifi-
cantly enhanced new bone formation.18 However, while a
substantial amount of new bone was formed under the
stimulation of Runx2, the engineered alveolar bone was
relatively loosening and more cancellous, suggesting that the
effect of Runx2 in directing the regenerative tissues toward
normal morphological and functional status was still not
satisfied for clinical application. Likewise, Osx has proved to
play an important role in bone tissue regeneration. It en-
hances proliferation and osteogenic potential of BMSCs
in vitro, and stimulates cascade of bone anabolic activity by
stimulating healing of critical-sized defects in murine cal-
varial bone.23,24 However, the regenerated calvarial bone in
Osx treated group was generally thinner and more delicate
than the native calvaria. In histological observation, acces-
sory structures such as bone sutures were not formed, sug-
gesting that possible factors that regulate embryonic bone
development are missing in the adult bone regeneration
process. We speculate that there might be other factors in-
volved in the morphogenesis and remodeling in bone re-
generation.
As a transcription regulator, SATB2 functions broadly and
plays an important role in craniofacial patterning and bone
development, making it a plausible candidate gene for bone
tissue engineering. SATB2 not only enhances osteogenic
differentiation through positively regulating expression of
multiple osteoblast-specific genes, but also promotes bone
formation and participates in branchial arch patterning
through repressing several Hox, genes including Hoxa2.10
Acting as a ‘‘molecular node’’ in a transcriptional network
FIG. 5. Surgical procedures and the
protocol for histomorphometric analy-
sis. (A) Under general anesthesia, a
submandibular incision was made,
and the masseter was lifted from its
insertion in the inferior mandibular
border to amply expose the mandible.
(B) A bone defect, 1.5mm in diameter,
was created on the bone overlying the
mandibular first molar with a dental
bur (#329, Midwest, 0.6mm in diame-
ter). (C) An isolated mandibular bone
with the 1.5mm bone defect. (D) The
mandibular bone samples were cut in
the coronal direction. The 6-mm-thick
tissue sections were numbered, and
the tissue sections positioned in lines a,
b, and c from each animal were col-
lected for further quantitative analysis.
(E) Representative photos indicating
tissue sections collected at positions a,
b, and c, respectively. Color images
available online at www.liebertonline
.com/tea
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regulating bone development and osteoblast differentiation,
SATB2 interacts with and enhances the transcriptional ac-
tivity of Runx2 and ATF4, two transcription factors that play
essential roles in inducing osteogenic differentiation.10 Con-
sistent with these previous findings, we found that SATB2
overexpression significantly enhances expressing levels of
bone matrix proteins and osteogenic transcription factors.
SATB2 also increases the expression level of VEGF, a major
angiogenic factor. Localized and sustained VEGF delivery
results in greater bone regeneration in calvarial defects than
observed with scaffold implantation alone.25 Furthermore, the
combined delivery of angiogenic and osteogenic factors has
been demonstrated to promote bone formation and healing.26
The upregulation of VGEF by SATB2 strongly indicated a
potential role of SATB2 in promoting angiogenesis during
tissue regeneration. The expression of SATB2 in DFCs of
molar tooth germs during root forming stage indicated that
SATB2 may also function in the process of root formation.
Recently, transgenic mice overexpressing Runx2 in osteo-
blasts under the control of the collagen I promoter have been
shown to exhibit severe osteopenia and fragile bones due to
inhibition of the late stage of osteoblast maturation.27 These
results suggest that new bone formation might occur more
efficiently and lead to bone matrix of better quality in vivo if
Runx2 levels are high during the early differentiation stage
and low during the osteoblast maturation stage. Our previ-
ous studies proved that although Osx did not increase Runx2
expression, it did promote bone regeneration, and a high
ratio of Osx to Runx2 at the late stages of osteoblast differ-
entiation may be essential for the efficient formation of newly
engineered bone.24 In this study, we found that SATB2 not
only upregulates Osx expression independent of Runx2, but
also synergistically enhances the increase in Osx expression
mediated by Runx2, demonstrated that by regulating the
ratio of other important transcription factors, SATB2 may
promote osteogenic differentiation and improve the quality
of newly formed bone.
Taken together, SATB2 can be a robust osteo-inductive
molecule recruiting other transcription factors to form a
platform or act as a molecular node for a transcriptional
network. It can synergize, amplify, and thus exponentially
augment the activity of multiple osteogenic transcriptional
factors, including Runx2, Osx, and ATF4, to regulate skeletal
development and osteoblast differentiation in craniofacial
reconstruction. Craniofacial and dental structures represent
the most complex organs in human body, and the applica-
tion of SATB2 in bone tissue engineering of the craniofacial
region may give rise to a higher bone forming capacity as a
result of multiple-level amplification of regulatory activity.
To investigate the capacity of SATB2 to promote bone
regeneration, we performed in vivo studies and transplanted
SATB2-transduced BMSCs or DFCs into bone defects created
in B6D2F1 mice. The BMSCs and DFCs used in this study
were isolated from a unique double-labeled transgenic
mouse line designated BSP-Luc/ACTB-EGFP mice.15 Briefly,
the b-actin promoter-driven EGFP enables us to identify
every exogenous cell from host cells present in the wound
sites, whereas the BSP promoter-driven luciferase is switched
on as the transplanted cells differentiate into osteoblasts or
cementoblasts. In this way, the in vivo role of SATB2 on the
survival, migration, and differentiation of the transplanted
BMSCs can be conveniently evaluated and confirmed.
Using these double-labeled cells and a mandibular bone
defect model, we found that SATB2 significantly enhances
regeneration of damaged mandibular bone tissues, as indi-
cated by increased new bone formation in bone defects
transplanted with SATB2-transduced adult stem cells. In
addition, IHC staining and cell counting results showed in-
creased luciferase-positive cells and BSP-positive cells in
bone defects transplanted with SATB2-transduced BMSCs
compared with those transplanted with control BMSCs,
although the amount of total transplanted cells in
FIG. 6. Histological analysis demonstrated increased bone
tissue regeneration and mineralization in bone defects ex-
posed to SATB2-overexpressing adult stem cells. (A, B)
H&E-stained sections showing bone defects transplanted
with control BMSCs (A) or SATB2-overexpressing BMSCs
(B). A2 and B2 are exactly the same images as A1 and B1,
respectively; however, we showed, in A2 and B2, the area
within the original bone lesion assessed by digitizing the
reversal line in the bone at the cut margin of the original
wound outline. (C) Histomorphometric analysis showed an
elevated newly formed bone area in bone defects treated
with SATB2-overexpressing BMSCs. Data were represented
as mean – SEM. *p< 0.05, SATB2 group versus control group.
(D, E) H&E-stained sections showing bone defects trans-
planted with control DFCs (D) or SATB2-overexpressing
DFCs (E). Again in D2 and E2, we showed the area within
the original bone lesion assessed by digitizing the reversal
line in the bone at the cut margin of the original wound
outline. (F) The newly formed bone area was higher in bone
defects treated with SATB2-overexpressing DFCs, as indi-
cated by histomorphometric analysis. Data were represented
as mean – SEM. *p< 0.05, SATB2 group versus control group.
Color images available online at www.liebertonline.com/tea
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SATB2-BMSCs group was similar to that in control-BMSCs
group, as represented by the number of EGFP-positive cells.
These results, together with our in vitro findings, indicated
that by orchestrating the expression of a group of osteogenic
transcription factors and matrix proteins, SATB2 stimulates
more adult stem cells to differentiate toward bone forming
cells and regenerate high-quality bone tissues in vivo. In oral
and maxillofacial surgery practice, a lack of sufficient mate-
rial precludes the universal use of autogenous bone, whereas
the use of allogenic bone for transplantation carries potential
risks of immune responses, pathogen transmission, and the
necessary immunosuppression. As a promising alternative
strategy to accelerate bone regeneration, application of
SATB2 in bone tissue engineering provides novel and im-
portant insights into gene-therapy and molecular control of
orofacial and dental tissue regeneration, which may be ap-
plied clinically for tissue engineering in future studies.
In conclusion, SATB2 orchestrates the expression of a
group of osteogenic transcription factors and matrix proteins
and thus plays a pivotal role in craniofacial development and
osteoblastogenesis. For the first time we initiate a new
strategy in bone tissue regeneration and reconstruction,
showing that SATB2 enhances the osteogenic capacity of
adult stem cells to regenerate new bone tissues with high
quality. These in vitro and in vivo findings shed light on the
understanding of cell differentiation processes in the com-
plex orofacial structures, and have a great potential in de-
veloping new gene-therapy approaches to treat the large
population of patients suffering from bone loss diseases.
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